Maryland State Retirement & Pension System bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 8,663 shares of the company’s stock, valued at approximately $1,591,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Key Financial Inc bought a new stake in shares of Krystal Biotech in the 2nd quarter valued at approximately $28,000. Crossmark Global Holdings Inc. purchased a new position in shares of Krystal Biotech during the second quarter valued at approximately $319,000. Principal Financial Group Inc. grew its stake in shares of Krystal Biotech by 1,972.0% during the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock valued at $22,674,000 after buying an additional 117,510 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Krystal Biotech by 3.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,461 shares of the company’s stock worth $819,000 after buying an additional 169 shares during the period. Finally, Legato Capital Management LLC bought a new stake in shares of Krystal Biotech during the 2nd quarter worth approximately $408,000. 86.29% of the stock is owned by institutional investors.
Krystal Biotech Trading Down 0.1 %
KRYS traded down $0.10 on Friday, reaching $195.12. The company had a trading volume of 202,918 shares, compared to its average volume of 360,353. Krystal Biotech, Inc. has a one year low of $93.95 and a one year high of $219.34. The company has a fifty day moving average of $194.04 and a 200-day moving average of $173.39. The company has a market capitalization of $5.57 billion, a P/E ratio of 104.34 and a beta of 0.84.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the stock. Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. HC Wainwright lifted their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday. Citigroup reissued a “neutral” rating and set a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and an average price target of $190.22.
Check Out Our Latest Report on Krystal Biotech
Insiders Place Their Bets
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.10% of the company’s stock.
Krystal Biotech Profile
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Recommended Stories
- Five stocks we like better than Krystal Biotech
- 3 Warren Buffett Stocks to Buy Now
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Comparing and Trading High PE Ratio Stocks
- Why Dell Can Continue Winning in AI and Beyond
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.